MBP and myeloid sarcoma: No significant differences in the levels of anti-MBP autoantibodies in the peripheral blood were found between the 39 healthy controls (7.74 ± 4.91 ng/mL), the 23 white matter lesion control group (4.69 ± 4.17 ng/mL), and the 136 patients with MS (4.05 ± 3.485 ng/mL).